Biolase Stock Jumps On Q1 Earnings Beat, Strong Demand For Dental Lasers, Q2 Outlook

  • Biolase Inc BIOL reported a Q1 EPS loss of $(0.06), which missed the analyst consensus of $(0.05) loss, though it improved from a loss of $0.19 reported a year ago.
  • Net revenue of $8.1 million beat the analyst consensus of $7.79 million and increase 70% Y/Y as Q1 2020 was impacted by the COVID-19 pandemic.
  • U.S. laser revenue of $2.9 million increased 200% Y/Y, consumables and other revenue increased 50% Y/Y.
  • International laser revenue increased 84% to $2.0 million, and consumables and other revenue were up 61%. Laser system sales increased 139% Y/Y.
  • The gross margin expanded to 34% from 29% last year, reflecting the impact of the increase in revenues from the COVID-19 pandemic and increased average selling prices for products sold in the U.S.
  • The company ended the quarter with $40.8 million in cash and cash equivalents.
  • Guidance: Biolase sees Q2 sales of $7.5 million - $8.5 million versus the consensus of $8.28 million.
  • Price Action: BIOL shares jump 29.3% at 0.75 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!